This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Haemonetics (HAE) Stock Up 4.2% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE), driven by a strategic focus on establishing leading positions in high-growth markets and raised guidance.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) strength in business raises optimism about the stock.
Haemonetics' (HAE) Plasma Growth, Innovation Aid Performance
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Philips (PHG) Adds BlueSeal to its Diagnostic Imaging Portfolio
by Zacks Equity Research
Philips (PHG) showcases BlueSeal MR Mobile to enhance diagnostic imaging capabilities across remote and rural communities.
Zacks Industry Outlook Highlights DaVita, Option Care Health, Addus HomeCare and Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch in an Evolving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, OPCH, ADUS and PNTG are well-poised to gain.
Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Cardinal Health (CAH) Gets FDA Warning for Monoject Syringes
by Zacks Equity Research
The FDA is alerting healthcare providers and facilities against the use of Cardinal Health's (CAH) Monoject syringes with syringe pumps and PCS pumps.
Insulet (PODD) Up 31.5% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Insulet (PODD) continues to gain from the strong adoption of Ommipod 5 and market expansion.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Fresenius Medical (FMS) Ups '23 Outlook After Legal Settlement
by Zacks Equity Research
Fresenius Medical (FMS) wins legal dispute against the U.S. government. Both revenues and operating income will benefit from the settlement agreement.
Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Patterson Companies (PDCO) Partners With Pearl for AI Services
by Zacks Equity Research
Patterson Companies (PDCO) collaborates with dental AI solution provider, Pearl, to integrate the latter's Second Opinion software solution within its Eaglesoft software to deliver advanced solutions.
Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.
Masimo's (MASI) W1 Medical Watch to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the latest FDA approval is expected to provide greater visibility of changes in oxygen saturation to help patients better manage their oxygen levels daily.
Why You Should Add Integer Holdings (ITGR) to Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
McKesson (MCK) Announces Availability of FDA-Cleared mCRC Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for mCRC.
Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales
by Zacks Equity Research
Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.
Best Growth Stocks to Buy for November 16th
by Zacks Equity Research
MDV, LZ and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 16, 2023.
Encompass Health (EHC) Opens Hospital to Boost Presence in Texas
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.
Avantor's (AVTR) New Offerings to Aid Cell and Gene Therapy Suite
by Zacks Equity Research
Avantor's (AVTR) latest offerings are likely to provide its customers with products, materials and services that would aid in accelerating therapeutics.
Masimo's (MASI) Latest Tie-Up to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) latest joint effort is likely to enable real-time continuous monitoring with a tailored view of the patient's vitals while keeping them mobile during critical recovery periods.